Infantile Spasms Clinical Trial
Official title:
A Double-blind, Placebo-controlled, Dose-ranging Clinical Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Treatment of Patients With Infantile Spasms
The study consists of cohorts where participants are randomized, in a 2:1 ratio, to 1 of 2 sequences, A and B. In each cohort, Sequence A, comprised of participants, who will receive ascending doses of ganaxolone and ascending doses of placebo. Sequence B, comprised of participants, who will receive ascending doses of placebo and ascending doses of ganaxolone. The dosing level in each subsequent cohort will be based upon experience gained from previous cohorts.
Male or female, 4 to 24 months of age (inclusive) with a diagnosis of IS with a 24 hour video EEG (vEEG) recording confirming the diagnosis and previously treated with 3 or fewer antiepileptic drugs (AEDs) are eligible for the study. The subject is able to continue treatment with concomitant AEDs (no more than 2; adrenocorticotropic hormone [ACTH], corticosteroids, felbamate, and vigabatrin are not allowed concomitantly). A ketogenic diet is permitted if it can be maintained for the duration of the study. There will be a total of three weekly 24-hr video EEGs (baseline, end of weeks 1 and 2 of treatment). Dosing titration begins the day after each video EEG during the inpatient stay. All subjects will be receiving ganaxolone the day after the second video EEG. A Data Monitoring Board (DMB) will determine whether successive cohorts of subjects can be dosed at an increased dose level; up to a maximum of 6 cohorts. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02299115 -
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
|
Phase 3 | |
| Completed |
NCT02885389 -
Molecular Genetics in Infantile Spasms
|
N/A | |
| Completed |
NCT01006811 -
Use of the Modified Atkins Diet in Infantile Spasms
|
Phase 2/Phase 3 | |
| Completed |
NCT01828437 -
Addition of Pyridoxine to Prednisolone in Infantile Spasms
|
Phase 3 | |
| Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
| Completed |
NCT00552045 -
Epilepsy Phenome/Genome Project
|
||
| Not yet recruiting |
NCT06315829 -
Artificial Intelligence-based Video Analysis to Detect Infantile Spasms
|
||
| Completed |
NCT02220114 -
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
|
N/A | |
| Completed |
NCT02954887 -
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
|
Phase 3 | |
| Completed |
NCT01723787 -
Genetic Studies in Patients and Families With Infantile Spasms
|
||
| Completed |
NCT02092883 -
Evaluation of Neuroinflammation in Children With Infantile Spasms
|
Phase 4 | |
| Withdrawn |
NCT01413711 -
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
|
Phase 4 | |
| Terminated |
NCT00442104 -
Open-label Extension to Protocol 1042-0500
|
Phase 2 | |
| Completed |
NCT01575639 -
Prednisolone in Infantile Spasms- High Dose Versus Usual Dose
|
Phase 3 | |
| Withdrawn |
NCT01549288 -
Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy
|
Phase 2/Phase 3 | |
| Completed |
NCT01073579 -
Sabril Patient Registry
|
N/A | |
| Completed |
NCT02953548 -
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
|
Phase 3 | |
| Completed |
NCT00001325 -
Metabolic Abnormalities in Children With Epilepsy
|
N/A | |
| Completed |
NCT00968136 -
Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study
|
N/A |